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Lon now emerges as a major regulator of multiple mitochondrial functions in human beings. Lon catalyzes the degradation of oxidatively
modified matrix proteins, chaperones the assembly of inner membrane complexes, and participates in the regulation of mitochondrial gene
expression and genome integrity. An early result of Lon downregulation in WI-38 VA-13 human lung fibroblasts is massive caspase 3
activation and extensive (although not universal) apoptotic death. At a later stage, the surviving cells fail to divide, display highly abnormal
mitochondrial function and morphology, and rely almost exclusively on anaerobic metabolism. In a selected subpopulation of cells, the
mitochondrial mass decreases probably as a result of mitochondrial inability to divide. At this final point the Lon-deficient cells are not
engaged anymore in apoptosis, and are lost by necrosis or bmitoptosis.Q Our results indicate that mitochondrial Lon is required for normal
survival and proliferation; a clear impetus for Lon’s evolutionary conservation.
D 2004 Elsevier Inc. All rights reserved.Introduction
Lon is the best evolutionarily conserved ATP-stimulated
protease [1], with homologues identified in a number of
bacterial species such as Escherichia coli [2], Bacillus brevis
[3], and Myxococcus xantus [4,5]; the yeast Saccharomyces
cerevisiae [6]; and the mitochondria of mammals [7–9]. This
high level of conservation suggests that Lonmight play a very
important role in the maintenance of mitochondrial homeo-
stasis, and in the bioenergetics and survival of cells.
In E. coli, the Lon gene product, protease La, is involved
in the degradation of abnormal polypeptides [10,11], and a
number of short-lived proteins with important regulatory
functions. These include the SOS response proteins, UmuD
and UmuC [12], the DNA damage-induced SulA which acts
as a cell division inhibitor after ultraviolet light damage0891-5849/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.freeradbiomed.2004.11.017
Abbreviations: mt, mitochondrial; EMEM, Eagle’s minimum essential
medium; EPEI, ethoxylated polyethylenimine; PI, propidium iodide; BrdU,
bromodeoxyuridine; TMB, tetra-methylbenzidine; FBS, fetal bovine serum.
* Corresponding author. Fax: (213) 740 6462.
E-mail address: kelvin@usc.edu (K.J.A. Davies).[13], and RcsAwhich is involved in capsular polysaccharide
synthesis [14]. Lon-deficient E. coli cells display a number
of unusual phenotypic features, such as filamentous growth
[15], mucoid colony formation [14], and an extended
growth lag when shifted from a rich to a minimal medium,
because of their inability to degrade free ribosomal proteins
and generate amino acids required for the synthesis of key
adaptative enzymes [16].
The yeast homologue PIM 1 performs essential functions
in yeast mitochondria. Dpim1 mutants are respiratory
deficient, are unable to utilize nonfermentable substrates
as their sole carbon source [6,17], and have impaired ability
to degrade mitochondrial matrix proteins which tend to
accumulate as electron-dense inclusions [17]. In addition,
these strains are unable to maintain functional mitochondrial
(mt) DNA [18,19]. Stabilization of mtDNA in Dpim1
mutants depends on protein degradation, and has been
achieved only by expressing a proteolytically active Lon
variant [20]. PIM1 involvement in DNA maintenance might
be explained by the fact that the human homolog of PIM1 is
able to bind to mitochondrial promoters, and may control
mitochondrial DNA replication and gene expression byMedicine 38 (2005) 665–677
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cation [21], or modulating the accumulation/activation of
regulatory proteins involved in preserving the integrity of
the mitochondrial genome [22]. The chaperone function of
PIM1 is independent of its proteolytic function. Therefore,
overexpression of even a proteolytically inactive PIM1 can
rescue the defects in respiration-dependent growth and inner
membrane complex assembly generated by inactivation of
the Afg3p and Rca1p AAA metalloproteases [23].
The functions of themammalian Lon protease are less well
described, although aconitase [24] and the SP-22 mitochon-
drial protein [25] have been identified as substrates.
Mammalian Lon can also act as a chaperone, independent
of its proteolytic activity, and it promotes the assembly of
cytochrome c oxidase (COX) subunits. Recently published
data [26] show that in vitro the human Lon protease binds GT-
rich DNA sequences overlapping the light-strand promoter of
human mtDNA as well as GT-rich sequences on the heavy
strand of mtDNA and GU-rich RNA. Lon protease also
interacts wit mtDNA polymerase g and the twinkle helicase,
in a yet unknown mechanism [26]. Lon expression occurs at
different levels in all human tissues so far studied [27,28], and
is modulated by aging [29]. Enhanced mitochondrial bio-
genesis is associated with increased expression of the Lon
protease [30], and both endoplasmic reticulum stress and
hypoxia seem to be able to induce its production [31].
We have previously reported that Lon downregulation,
by antisense oligomorpholine treatment of WI-38 VA-13
human lung fibroblasts, leads to impaired mitochondrial
proteolysis and accumulation of both native and oxidized
aconitase [24]. We next reasoned that an antisense oligo-
morpholine approach to study Lon functions, by gradually
increasing Lon deficiency (recognizing that a Lon deletion
mutant would be lethal), actually provides an excellent
opportunity to test whether the multiple roles proposed for
Lon in bacteria and lower eukaryotes are relevant to human
beings. Therefore, we now report how the various cellular
roles that Lon plays are sequentially affected by Lon
downregulation, and how loss of Lon functions compro-
mises the performance and survival of human cells.Experimental procedures
Materials
All chemicals and reagents were obtained from Sigma
unless otherwise specified.
Cell culture and cell survival/proliferation analysis
Human WI-38 VA-13 lung fibroblasts (ATCC) were
grown in Eagle’s minimum essential medium (EMEM)
supplemented with 10% fetal bovine serum, penicillin (100
units/ml), and streptomycin (100 Ag/ml). The cultures were
grown under an atmosphere of 19.9% oxygen and 5% CO2in a humidified 5% CO2 incubator, at 378C. Cells were
subcultivated at confluency. The medium was changed
every other day before the oligonucleotide treatment and
every day after the oligonucleotide treatment.
For the analysis of cell survival/proliferation, live,
attached cells were harvested by trypsinization at various
time points and counted in a Z1S Coulter Particle counter
(Coulter). Pictures of cells were also taken, at various times,
using a Nikon Phase Contrast 2 microscope at 10
magnification.
Oligonucleotides and delivery
We used a custom (Gene Tools, LLC) antisense morpho-
lino oligonucleotide directed against the lon gene to down-
regulate lon in WI-38 VA-13 cells. This oligonucleotide
(CGTAGCCAGTGCTCGCCGCCATAGC) is complemen-
tary to bases 31 to 55 of lon exon 1. A standard control
sequence (CCTCTTACCTCAGTTACAATTTATA) that has
no target and no significant biological activity (Gene Tools,
http://www.gene-tools.com) was also tested. Delivery was
achieved by using a weakly basic delivery reagent, ethoxy-
lated polyethylenimine (EPEI). The cells were incubated in
the presence of the delivery system for a total of 3 h, as
suggested by the manufacturer. Final oligonucleotide con-
centration in the delivery medium was 1 AM. The delivery
medium was then removed, and the cells were grown in
fresh EMEM medium and harvested at the time points
described. The antisense morpholino oligonucleotide sys-
tem we used has high and predictable activity inside the
cell and is immune to nucleases, which allowed us to use a
single treatment [32]. Because of our previous experience
with this system [24], we were able to downregulate lon
very efficiently. Four days after treatment, we were no
longer able to detect Lon protein by Western blot analysis,
and the mitochondrial ATP-stimulated proteolytic activity
was 87% lower in the lon antisense oligonucleotide-treated
cells then in the control oligonucleotide-treated cells.
Apoptosis analysis by flow cytometry
Adherent WI-38 VA-13 cells (106 per experiment) were
collected and fixed in 70% ethanol for 2 h. After fixation, the
cells were pelleted and suspended in 1 ml propidium iodide
(PI)/ Triton X staining solution containing 0.1% Triton X-
100, 20 Ag/ml PI, and 200 Ag DNase-free RnaseA and
incubated for 30 min at room temperature. At the end of the
incubation time, the cells were subjected to fluorescence-
activated cell-sorting analysis of DNA content. The percent-
age of cells with subdiploid DNA content was taken as a
measure of the apoptotic rate of the cell population.
Z-VAD-FMK treatment and caspase-3 assay
WI-38 VA-13 human lung fibroblast cells treated with lon
antisense oligonucleotide or the matched control oligonu-
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FMK (Z-VAD-FMK), a caspase-3 inhibitor from Enzyme
Systems Products (Livermore, CA) was added to a final
concentration of 50 AM to the cell media after oligonucleo-
tide treatment. The cell media contained 2 Al of DMSO/ 1 ml
of EMEM, either as Z-VAD-FMK solvent or as a vehicle
control.
Caspase-3 activity was measured in cell extracts, using
CPP32/caspase-3 colorimetric protease assay kit from
MBL. WI-38 VA-13 human lung fibroblast cells (106)
were harvested 2, 4, 6, and 8 days after the treatment with
oligonucleotides, pelleted at 1500 rpm for 10 min, and
resuspended in cell lysis buffer (on ice). The supernatant
was separated from the pellet by centrifugation at 10,000g.
Two hundred micrograms of protein cell extract (super-
natant) was incubated with reaction buffer and 200 AM
DEVD-pNA substrate at 378C for 1 h. Protein concen-
tration was determined using the BCA assay (Pierce) or
the DC assay (Bio-Rad). Spectrophotometric detection of
the EVD-pNA cleavage product, pNA, was performed at
400 nm in a 96-well plate, using a Spectra Max 250 Plate
Reader (Molecular Devices). Background readings from
cell lysates and buffers were subtracted from the sample
values. The results were expressed as percentage of
readings from cell lysates of samples grown in the
presence of DMSO, but not subjected to the oligonucleo-
tide treatment.
Bromodeoxyuridine (BrdU) incorporation
We measured BrdU incorporation in adherent cells
using the BrdU cell proliferation assay from Oncoge-
ne.WI-38 VA-13 human lung fibroblast cells treated with
Lon antisense oligonucleotide, or the matched control
oligonucleotide were seeded 6 h before each experimental
point at a density of 104 cells per well in 96 well culture
dishes. We incubated the cells with BrdU for 2 h, and
then the cells were fixed and permeabilized. Monoclonal
anti-BrdU antibody was added to each well for 1 h, after
which the unbound antibody was washed away, and
horseradish peroxidase-conjugated secondary antibody
was added. Conversion of the chromogenic substrate
tetra-methylbenzidine (TMB) was measured after 15 min
of incubation in the dark, at dual wavelengths of 450–
540 nm, using a Spectra Max 250 plate reader
(Molecular Devices).
Uridine treatment
Uridine (Sigma) was prepared [33] as a 10 mg/ml
stock solution in distilled water, filter sterilized, and
stored at 208C. WI-38 VA-13 cells were grown after
the oligomorpholine treatment in the absence or
presence of uridine (100 Ag/ml). At various time points,
cells from individual plates were trypsinized and
counted.Respiration measurements
WI-38 VA-13 cells (107) were trypsinized, suspended
in 10 ml of complete culture media, and counted. After
centrifugation (1000g, 5 min), 5  106 cells from each
experimental group were suspended either in 1.5 ml of
air-saturated complete culture medium (for measurements
on intact cells) or in 1 ml of medium A (20 mM Hepes,
pH 7.1, 250 mM sucrose, and 10 mM MgCl2), for
measurements on permeabilized cells, as previously
described [33]. Permeabilization was achieved by adding
digitonin to 100 Ag/5  106 cells; a concentration that
permeabilizes the plasma membrane, but leaves the
mitochondrial membranes intact [34]. After addition of
digitonin, the cells were washed, collected by centrifuga-
tion (350g for 3 min), and resuspended in air-saturated
respiration medium (medium A, plus 1 mM ADP and 2
mM potassium phosphate). Oxygen consumption for
intact and permeabilized cells was measured with a
Clark-type oxygen electrode in a magnetically stirred,
water-jacketed cell, at 378C (Digital Model 10, Rank
Brothers, LTD), calibrated over 0–100% scale. The initial
oxygen concentration under these conditions was taken to
be 217 nmol/ml.
For the permeabilized cells, oxygen electrode record-
ings were continued after successively adding the
following substrates and inhibitors: glutamate (5 mM)
and malate (5 mM) for complex 1 activity measurement;
0.1 AM rotenone (complex 1 inhibitor) and succinate (5
mM) for complex 2 activity determination; 10 mM
malonate (complex 2 inhibitor) and a-glycerophosphate
(5 mM) for complex 3 activity; 20 AM antimycin
(complex 3 inhibitor) plus ascorbate (10 mM) and TMPD
(200 AM) as complex 4 substrates; and, finally, 0.1 mM
KCN to inhibit complex 4 activity [35,36]. These
compounds were added with individual Hamilton syringes
from 100 to 200 times concentrated frozen or fresh stock
solutions.
Transmembrane potential determination
Mitochondrial transmembrane potential was assessed
using the MitoLight (C25H27Cl3N4) Mitochondrial Indi-
cator from Chemicon International, Inc. Adherent cells,
4 days after oligonucleotide treatment, were grown in
12.5 cm2 plates and incubated with MitoLight for 1 h.
The cells were observed by fluorescence microscopy,
and pictures were taken in different fields. Green (527–
530 nm) and red (585–590 nm) channel fluorescence
was quantified by densitometry (IP Lab) and expressed
in arbitrary units.
Mitochondrial mass estimation by FACS analysis
WI-38 VA-13 human lung fibroblast cells were treated
with antisense lon morpholino oligonucleotide, or the
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treatment, the cells (5  105) were trypsinized and
incubated with Mito Fluor Red 589 (Molecular Probes)
for 45 min. Mito Fluor Red 589 accumulates in
mitochondrial membrane lipids (regardless of membrane
potential). FACS analysis was performed at 588 nm
(emission) and 622 nm (excitation), as recommended by
the manufacturer.
Electron microscopy analysis
WI-38 VA-13 human lung fibroblasts were harvested 4
days after the oligonucleotide treatment. We followed a
similar protocol to that used for visualization of mito-
chondrial defects produced by lon/pim1 downregulation in
S. cerevisiae [17]. The cells were prepared by fixation in
potassium permanganate, infiltrated with Spurr’s resin,
sectioned, and contrasted with Reynold’s lead citrate.
Pictures of mitochondrial defects were taken in many
different sections, at 10,000 and 20,000 magnification,
and the phenotypes described were equally widespread in
all the fields studied.Fig. 1. The impact of Lon protease downregulation on WI-38 VA-13 human fibro
matched control oligonucleotide, were grown in EMEM media supplemented with
the start of the experiment, and the cells were subcultured every other day. (A)
experiments in which Lon was visualized by Western blotting and quantified by
oligonucleotide treatment and results are means F standard errors. (B) At the time
(C) Pictures of the cells were taken 4 days after treatment under an inverted micResults
Lon-depleted cell phenotype is characterized by increased
cell death and inability to grow
We treated WI-38 VI-13 human lung fibroblasts with
morpholino oligonucleotides directed against the lon pro-
tease sequence, or with a control oligonucleotide, and we
obtained a significant downregulation of Lon in the
antisense oligonucleotide-treated cells. Four days later, we
were not able to detect Lon expression by Western blot in
the Lon-deficient cells (Fig. 1A), and the ATP-stimulated
proteolytic activity was 87% less in the cells treated with the
antisense lon oligonucleotide than in control cells, as
previously reported [24].
It is worth noting that our oligonucleotide delivery
protocol contains two potential causes for cell stress: the
ethoxylated polyethylenimine delivery reagent, and the
3 h of serum deprivation required during the delivery
stage. Polyethylenimine/DNA complexes have been
shown to induce cellular stress and concentration-depend-
ent cell death at up to 9 h after delivery [37], but noblasts. WI-38 VA-13 cells treated with lon antisense oligonucleotide, or the
10% FBS. Multiple 12.5 cm2 flasks were seeded with 106 cells 6 h before
Summary of total Lon protease levels (arbitrary units) from three different
densitometry (IP lab). The measurements were performed 4 days after the
points indicated, cells from individual plates were trypsinized and counted.
roscope. Representative pictures are shown.
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of apoptosis in various cell lines [38–40], and for
fibroblasts apoptosis becomes significant only after at
least 24 h [40]. However, even more sensitive cells, such
as neuronal precursors, fully recover their viability [38]
when serum-deprived for up to 4 h and then grown in
complete medium. Under our experimental conditions, no
significant cell death/detachment was observed in the
cells treated with the control oligonucleotide/EPEI com-
plex, and the same doubling time of 2 days (similar to
the doubling time of WI-38 VI-13 fibroblasts grown in
regular media without any treatment) was observed in
cells treated with the control oligonucleotide for the
entire 10-day period studied.
When we counted the number of live, attached cells in
the cell flasks treated with the antisense lon oligonucleo-
tide/EPEI complex, consistently less cells were found than
in the control oligonucleotide-treated cells, despite the fact
that both cultures started with a similar number of cells
(Fig. 1B). Two days after the treatment, cells treated with
control oligonucleotide had more than doubled their
number, from 0.78  106 to 1.73  106, a 120% increase.
In contrast with these control results, cells treated with the
lon antisense oligonucleotide only increased their cell
number by 60% during the first 2 days after treatment.
After 2 days, the number of cells in the colonies treated
with lon antisense oligonucleotide actually began to
decline, from 1.3  106 cells counted 2 days after
treatment to 0.9  106 cells on the fourth day of the
experiment; a cell number four times lower than that of the
control cells. The number of lon antisense oligonucleotide-
treated cells continued to decrease by a similar percentage
(30%) between Day 4 (0.9  106) and Day 6 (0.64  106),
and then remained stagnant for the next 2 days.
An increased number of dead, detached cells were
observed floating in the culture media of the Lon-deficient
cells. When pictures of the cell plates were taken (Day 4),
two characteristics were observed: (1) the antisense lon-
treated cells were less numerous, and (2) a significant
percentage of the cells still present on the plates were
partially detached (Fig. 1C).
Lon downregulation induces early apoptotic cell death in
WI-38 VA-13 fibroblasts by a mechanism involving caspase-3
To examine the cause of cell death in the WI-38 VA-13
fibroblasts we used flow cytometric analysis of the DNA
content (Fig. 2A). Reduced fluorescence of propidium
iodine-stained DNA has been described in apoptotic cells,
initially as a consequence of chromatin condensation to a
state of reduced accessibility [41] and, at a later stage,
because of partial loss of DNA content due to activation of
endogenous endonuclease and diffusion of the low mole-
cular weight fragments from the cells [42]. It has also been
shown that necrosis does not result in generation of a DNA
subdiploid peak [43,44]. Four days after treatment, thepercentage of adherent lon antisense oligonucleotide-treated
cells having a subdiploid DNA content was 6.8%, sixfold
more than the percentage of subdiploid cells in the control
group (1.1%). This number actually underestimates apopto-
sis because it includes only the apoptotic cells that were still
attached to the plates, and not the cells that were already
detached and floating in the media. The number of cells that
actually died by apoptosis could be calculated as the diffe-
rence between the predicted cell number (from controls) and
the actual cell number, divided by the growth rate estimated
by bromodeoxyuridine incorporation. Using this approach it
appears that apoptotic cell death was actually closer to 26%
between Days 0 and 2, and 69% between Days 2 and 4 of
antisense treatment (see Discussion for more details).
Since caspase-3 is a key enzyme involved in the early
stages of apoptosis [45,46], we next analyzed cell survival
and caspase-3 activity in cells treated with lon antisense or
control oligonucleotides, and grown in the presence or
absence of the caspase-3 inhibitor, Z-VAD-FMK (Figs. 2B
and C). As previously described [24], after treatment with
lon antisense oligonucleotides, Lon protease expression and
activity declined and cell number began to decrease (Fig.
2B). Cell death was an important cause of this decline in
overall cell number. In contrast, cells treated with the control
oligonucleotide grew normally, and cell numbers increased
from 3.75  106 to 9.68  106 between Days 0 and 6.
Between Day 0 and Day 4, the survival of lon antisense
oligonucleotide-treated cells was improved by Z-VAD-FMK
treatment, and the cell number in this group increased 100%
by Day 2, and 40% between Day 2 and Day 4. Z-VAD-
FMK was less effective in increasing the cell number after
Day 4 (41% increase between Days 4 and 6, and 14%
increase between Days 6 and 8), suggesting that a second,
different mechanism might be also involved in slow growth
at the later stages of Lon deprivation (Fig. 2B).
When using oligonucleotides it is important to determine
if the delivery protocol itself is toxic or even apoptotic. No
significant cell death was seen in the control oligonucleotide-
treated cells; however, even though, on the second day after
treatment, the level of caspase-3 activity was almost double
the baseline caspase-3 activity in nontreated cells (Fig. 2C).
In accord with this observation, although Z-VAD-FMK
addition effectively decreased the caspase-3 activity in these
cells (Fig. 2C), it failed to cause any significant increase in
cell number in the control group (Fig. 2B), suggesting that
apoptosis was not a significant problem. Four days after
transfection, the control oligonucleotide-treated cells had
reduced their caspase-3 activity to baseline levels. This
apparent paradox at low levels of caspase-3 activation has
been seen before [47], and is probably explained by the cells
ability to recover from a partial caspase-3 (potentially pro-
apoptotic) stimulus, without necessarily entering apoptosis.
In contrast, the antisense lon oligonucleotide-treated cells
had a much higher activation of caspase-3: 2 days after the
start of the experiment, caspase-3 activity was 600% higher
than baseline levels, and declined more slowly (still 230%
Table 1
WI-38 VA-13 Lon-depleted cells exhibit diminished proliferation potential,
as measured by bromodeoxyuridine (BrdU) incorporation
Lon antisense oligo.
treatment
Control oligo.
treatment
Day 2 83.8 F 3.7% 74.0 F 9.6%
Day 4 61.0 F 1.6% 83.1 F 4.5%
Day 6 51.3 F 5.7% 124.0 F 9.8%
Day 8 77.3 F 3.1% 161.0 F 11.6%
WI-38 VA-13 human lung fibroblast cells treated with lon antisense
oligonucleotide or the matched control oligonucleotide were seeded 6 h
before each experimental point at a density of 104 cells per well into 96 well
culture plates. The cells were then incubated with BrdU for 2 h. BrdU
incorporation was estimated by enzyme immunoassay (Oncogene), at the
time points indicated, and quantified as absorbance (450–550 nm). The
results are expressed as percentage of incorporation in untreated cells,
where 100% represents BrdU incorporation for cells not subjected to any
oligonucleotide treatment.
Fig. 2. Lon protease deficiency causes early apoptotic cell death by a caspase-3-dependent mechanism. (A) WI-38 VA-13 cells treated with lon antisense
oligonucleotides display subdiploid (SD) DNA content. Lon antisense and control oligonucleotide-treated cells were harvested 4 days after treatment, and
subjected to propidium iodine staining and flow cytometric analysis of DNA content. The total number of cells analysed for each experiment was 15,000. (B)
Z-VAD-FMK improves cell survival. WI-38 VA-13 human lung fibroblasts treated with lon antisense oligonucleotide or the matched control oligonucleotide
were grown in 25 cm2 flasks. Z-VAD-FMK was added to a final concentration of 50 AM to the cell media, which always contained 2 Al of DMSO/1 ml of
EMEM, either as Z-VAD-FMK solvent or as the vehicle control. At the time points indicated, cells from individual plates were trypsinized and counted. (C)
Caspase-3 activity levels. Caspase-3 activity was measured in cell extracts, at the time points indicated, using a CPP32/caspase-3 colorimetric protease assay
kit (MBL), based on the spectrophotometric detection of the DEVD-pNA cleavage product, pNA. Each reaction well contained 200 Ag protein cell extract
and 200 AM DEVD-pNA substrate. The results are expressed as a percentage of readings from cell lysates of samples grown in the presence of DMSO, but
not subjected to any oligonucleotide treatment. In panels B and C the results are means F standard errors of six independent determinations.
D.A. Bota et al. / Free Radical Biology & Medicine 38 (2005) 665–677670after 4 days), without reaching baseline levels even 8 days
after the transfection (Fig. 2C). These results confirm that
apoptotic cell death is amplified by Lon downregulation, and
explains why the Z-VAD-FMK addition is able to partially
rescue the survival and proliferation of cells during Lon
deficiency.
Lon deficiency in human fibroblasts is characterized by low
bromodeoxyuridine incorporation and increased
generation time
To further investigate the other possible factor causing a
lag in cell number, we decided to estimate cell proliferation
from the rate of incorporation of bromodeoxyuridine.
Although on the second day the cells treated with lon
antisense oligonucleotide and control oligonucleotide had
similar proliferation rates, 6 days after treatment, the lon
antisense-treated cells were proliferating at a rate 2.5 times
slower than the control cells (Table 1). The lon antisense
oligonucleotide-treated cells were still growing at a reduced
rate at a time when the caspase-dependent apotosis was
markedly reduced. This slow rate of proliferationmay explain
why, though not undergoing apoptosis, the Lon-deficient
cells still had a slower generation time than the control cells.Lon proteolytic dysfunction causes accumulation of
aggregated proteins in mitochondria
We have previously shown that diminishing Lon levels
by treatment with antisense lon oligonucleotides causes the
accumulation of both native and carbonylated (oxidized)
mitochondrial aconitase as early as the second day after
D.A. Bota et al. / Free Radical Biology & Medicine 38 (2005) 665–677 671treatment [24]. Accumulation of oxidized, inactivated
aconitase was linked with decrease in aconitase activity
both in our system [24] and in aging Drosophila [48] and
MnSOD-deficient mice [49]. In the invertebrate system, the
inactivation of aconitase has been associated with reduced
lifespan. We can now extend these results at a morpho-
logical level, by electron microscopy.
Thin-section electron microscopy of control oligonucleo-
tide-treated cells at 20,000 magnification (Fig. 3) revealed
mitochondria with the normal profiles of round/ovoid
shapes, numerous cristae, and almost transparent matrix
(Fig. 3A). In contrast, the mitochondrial matrix of Lon-
deficient cells contained electron-dense inclusion bodies, a
phenotype previously seen in the Dpim1 yeast strain [17]
and proposed to be caused by aggregated proteins (Fig. 3C).
The membranes also had increased electron density pro-
bably also due to the accumulation of undegraded or
unfolded proteins (Fig. 3C), due to the loss of both the
proteolytic and the chaperone activities of the Lon protein.
We also identified giant mitochondria in which the matrix
space was filled with electron-dense inclusions (Fig. 3C),
that structurally resembled the lack of segmentation and the
filamentous growth seen in E. coli Lon/La mutants [15].
Finally, we observed many empty giant vacuoles, which
may be generated by opening of the permeability transition
pores of giant mitochondria (Fig. 3D). Some mitochondria
had little or no cristae (Fig. 3B), and resembled U0Fig. 3. Mitochondrial defects caused by Lon downregulation. WI-38 VA-13
oligonucleotides were harvested 4 days after the treatment. The cells were prep
sectioned, and contrasted with Reynold’s lead citrate. Pictures of mitochondrial d
were equally widespread in all the fields studied.mitochondria, and Dpim1 yeast [17], which are also
deficient in intact mtDNA due to the loss of Lon’s protective
function in mtDNA maintenace [6].
Loss of Lon function as a chaperone and/or regulator of
mitochondrial gene expression may cause impaired
respiration and pyrimidine auxotrophy
Since Lon may function as a chaperone involved in the
folding and assembly of respiratory complexes independent
of its proteolytic activity, and/or may promote stability and
replication of the mitochondrial genome, we predicted that
respiratory function would be strongly affected by Lon
deficiency.
We measured cell respiration, both in intact cells and in
digitonin-permeabilized cells, in the presence of a number
of mitochondrial respiratory substrates, 4 days after the
oligonucleotide treatment, when Lon levels were virtually
undetectable [24]. The respiratory rate of intact cells in
growth media was five times lower during Lon deficiency
than in normal growth, and was similar to the respiratory
impairment reported in Dpim1 yeast cells [6,17]. We also
measured maximal oxygen consumption rates of individual
respiratory complexes in digitonin-permeabilized cells.
Using glutamate and malate as complex 1 substrates, the
oxygen consumption rate was decreased by 70%. At
complex 2 (succinate) the decrease was also 70%, while athuman lung fibroblasts exposed either to lon antisense or to control
ared by fixing in potassium permanganate, infiltrated with Spurr’s resin,
efects were taken in many different sections, and the phenotypes described
D.A. Bota et al. / Free Radical Biology & Medicine 38 (2005) 665–677672complex 3 (glycerophosphate) and complex 4 (ascorbate
and TMPD) respiratory rates were respectively 55 and 53%
lower in cells treated with the lon antisense oligonucleotides
than in control cells (Fig. 4A).
The activity of various other enzymes situated in the
mitochondrial inner membrane also requires mitochondrial
electron transport for normal function. Among the most
important of these is dehydrooratate dehydrogenase, an
enzyme in the pyrimidine biosynthetic pathway, that is
required for the production of uridine [50]. The need for
exogenous uridine addition for cell growth and division is
considered a marker for severely dysfunctional mitochon-
dria, and was first associated with (U0) mitochondria lacking
mtDNA [33]. Our Lon-deficient cells were also uridine
deficient, as evidenced by the fact that we were able to
stimulate division of the lon antisense-treated cells when we
supplemented the growth medium with uridine. After 4 days
in the presence of uridine, the growth rate significantly
increased (Fig. 4B).
Early loss of mitochondrial transmembrane potential and
late decline in mitochondrial mass characterize the
lon-deficient phenotype
In order to further investigate the mitochondrial defects
leading to low oxygen consumption capacity and a require-
ment for uridine to sustain cell growth, we next measured
mitochondrial transmembrane electrical potential (Dc). At
the same time when other mitochondrial markers became al-
ered (Day 4 after the oligonucleotide treatment), we stained
cells using MitoLight (C25H27Cl3N4) dye [51] (Fig. 5A).
As expected from our study of respiration (Fig. 4), the
Lon-deficient cells had decreased transmembrane poten-Fig. 4. Lower respiratory rates and uridine auxotrophy after lon antisense oli
mitochondrial respiratory rates. WI-38 VA-13 human lung fibroblasts were treated
Four days after treatment, the cells were harvested, and respiratory rates were calcul
106 cells in each assay. Substrates used included glutamate + malate (complex I),
TMPD (complex IV) substrates. Oxygen consumption was measured using a R
Experimental procedures. (B) WI-38 VA-13 Lon-depleted cells display pyrimidi
treatment in the absence or presence of uridine (100 Ag/ml). At the time points indica
A and B all data points shown are the means F standard errors of six independential, as shown by the fact that MitoLight accumulated
mostly inside the cytoplasm where it was measured
predominantly on the green channel. In contrast, in the
control oligonucleotide-treated cells, MitoLight was trans-
ported inside the active mitochondria, and a significant
fraction was visualized on the red channel (Fig. 5B). This
result is in agreement with recently published data,
showing that Lon overexpression can protect mitochondria
from loss of membrane potential following hypoxia and
ER stress [31].
We also wanted to determine if the apparent decrease in
accumulation of MitoLight inside the lon antisense oligo-
nucleotide-treated cells was indeed due to diminished
mitochondrial trans-membrane potential, or to a decline in
the total number of mitochondria inside these cells. When
we used a mitochondrial dye, Mito Fluor Red 589, which
accumulates inside mitochondrial membrane lipids, regard-
less of membrane potential, we were not able to detect any
difference in the total mass of mitochondrial membranes
between the two experimental groups by FACS analysis 4
days after treatment (Fig. 6). Two days later however, on
Day 6, a population of cells with less mitochondria began to
appear in the cells with decreased Lon content (indicated by
the arrow in the bottom right panel of Fig. 5). This
observation validates the hypothesis that Lon is involved
in mitochondrial biogenesis [30], and may explain the
similarity but lack of complementation between the Dpim1
and the U0 strains in yeast [6,17].
The combined results of Figs. 5 and 6 provide good
evidence for an early loss of mitochondrial transmembrane
potential, followed by a subsequent decrease in overall
mitochondrial mass, during Lon antisense-induced Lon
deficiency.gonucleotide treatment. (A) Lon deficiency causes reduced cellular and
with lon antisense oligonucleotide, or the matched control oligonucleotide.
ated for the intact cells as well as for digitonin-permeabilized cells using 5
succinate (complex II), glycerol 3-phosphate (complex III), and ascorbate +
ank Brothers, Clark-type electrode in 1.5 ml medium, as described under
ne auxotrophy. WI-38 VA-13 cells were grown after the oligomorpholine
ted, cells from individual plates were trypsinized and counted. In both panels
t determinations.
Fig. 5. Decreased mitochondrial transmembrane potential in lon antisense oligonucleotide-treated WI-38 VA-13 cells, measured by fluorescence microscopy.
(A) WI-38 VA-13 human lung fibroblast cells were treated with antisense lon oligonucleotide, or the matched control oligonucleotide. Four days after
treatment, adherent cells were stained with MitoLightTM (C25H27Cl3N4) from Chemicon. (B) Summary of means and standard errors of green (527–530 nm)
and red (585–590 nm) channel fluorescence from three individual experiments, quantified by densitometry (IP Lab) and expressed in arbitrary fluorescence
units.
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energy metabolism
The Lon-deficient cells needed frequent media changes
to maintain pH, and to replenish glucose/pyruvate stores.
During all our experiments involving Lon-deficient cells,
daily changes of Eagle’s minimum essential medium were
required in order to maintain the cells attached to the culture
plates. Furthermore, the 1-day-old media were already
acidic, as shown by the color change of the pH marker,Fig. 6. Decreased mitochondrial mass in lon antisense oligonucleotide-treated W
fibroblast cells were treated with antisense lon oligonucleotide, or the matched
trypsinized and stained with Mito Fluor Red 589 (Molecular Probes), which accum
FACS analysis was performed at 588 nm (emission) and 622 nm (excitation), as
several experiments.Phenol Red, from pink to light yellow. These, and other
observations show that the Lon-deficient cells were largely
dependent on anaerobic energy metabolism.
Cell death estimation as a function of actual cell number
and proliferation rates
We have calculated the percentage of cells that died at
intervals of 2 days, by estimating the predicted number of
cells at the end of each interval, based on the growth ratesI-38 VA-13 cells, measured by FACS analysis. WI-38 VA-13 human lung
control oligonucleotide. Four and 6 days after treatment, the cells were
ulates in mitochondrial membrane lipids (regardless of membrane potential).
recommended by the manufacturer. The data shown are representative of
Fig. 7. Lon-deficient cell death patterns after Z-VAD and uridine treatment. (A) Lon antisense oligonucleotide-treated cells were counted every second day after
the transfection treatment. At the same points in time, the rate of cell growth estimated by BrdU incorporation was measured. The number of cells that died was
calculated as the difference between the predicted cell number and the actual cell number, divided by growth rate. (B) Schematic representation of stages of Lon
deficiency in WI-38 VA-13 fibroblasts from apoptosis to selection of survivor cells with reduced mitochondrial mass.
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difference between the predicted number of cells and the
actual number measured was considered to represent the
predicted progenies of cells that died, and this difference was
divided by the growth rate, in order to calculate the actual
number of cells that died instead of dividing (Fig. 7A).
Using this algorithm, we were able to calculate that,
during Lon protease deficiency, an increased number of cells
died between Day 2 and Day 6, and then the cell death rate
declined, reaching baseline after 8 days. The two agents that
we used to compensate for Lon deficiency acted at different
stages of Lon-induced lethality. Z-VAD-FMK was able to
reduce cell death almost completely in the first 4 days but it
became less efficient after Day 4, and exerted no effect at all
by Day 6. In contrast, uridine addition had only a small effect
during the initial phase of massive apoptosis, but effectively
reduced cell death by 50% at Day 4, and even reestablished
normal cell growth and division by Day 6. This temporal
pattern probably argues for two types of cell death induced
by loss of Lon function: an initial apoptosis followed by
mitochondrial dysfunction, ATP deficiency and eventual
necrosis, and final selection of survivor cells with diminished
mitochondrial content (Fig. 7B).Discussion
Very little information is available about the function of
the Lon protease in higher organisms, especially humans. In
this paper, we analyze the first human cell model of Lon
deficiency, obtained by downregulating Lon expression in
WI-38 VA-13 human lung fibroblasts [24]. Since the E. coliprotease La and the yeast Lon protease have been more
extensively studied, we also compared our results with
previously published observations on these two organisms.
Lon downregulation in WI-38 VA-13 human lung
fibroblasts elicits two temporally and mechanistically
distinctive patterns. Initially, loss of Lon activity causes
massive apoptosis, with the classic hallmark of caspase-3
activation. At this early stage we can also partially im-
prove cell survival by addition of the caspase-3 inhibitor,
Z-VAD-FMK. Two Lon functions seem to be mostly
involved in this early apoptosis: the proteolytic defect causes
accumulation of aggregated proteins inside mitochondria;
while loss of chaperone function severely affects mitochon-
drial respiration and membrane potential, rendering cells
extremely susceptible to apoptotic stimuli. At a later stage,
the surviving cells lose their ability to undergo apoptosis, and
are respiratory deficient and unable to divide due to defects
in uridine synthesis. Lon involvement in mitochondrial
division and maintenance of mitochondrial mass also
becomes apparent, as a population of cells with diminished
mitochondrial content emerges.
Inhibitors of respiratory complexes, such as rotenone [52]
and antimycin [53], have previously been shown to be able to
cause apoptosis, and the availability of intracellular ATP
plays a major role in cell survival or the type of cell death
[54,55]. The demise of cells after an apoptotic trigger has
been shown to be a continuum governed by the intracellular
ATP concentration: cells with adequate energy supplies
undergo apoptosis, while cells with progressive ATP
depletion switch to cell death with mixed features (apopto-
necrosis), and then, finally to necrosis [53,56]. We propose
that the type of cell death in the Lon-deficient cells is also
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mitochondrial defects at both a functional (loss of aerobic
respiration and membrane potential) and a morphological
level, involving accumulation of aggregated, oxidatively
damaged proteins, such as aconitase [24], or unassembled
respiratory chain subunits [23,31]. Thus, while apoptosis
predominates in the early days after transfection, energy
production is subsequently compromised and the cells enter
growth arrest and necrosis. It is entirely possible that the cell
death pattern observed between Days 4 and 8 of lon antisense
treatment may actually conform to the mitoptosis pathway
proposed by Skulachev [57,58]. The fact that lon down-
regulation can induce apoptosis or render cells more sensitive
to apoptotic stimuli is especially important since in other
systems where decreased Lon levels have been described,
i.e., aging [29] and Sod2/+ murine muscle [59], increased
rates of apoptotic cell death [60,61] have also been reported.
Most of the mitochondrial dysfunctions described in this
paper seem to be caused by a combination of the three
functions of Lon described in eukaryotes, and in addition,
mimic some of the lon/la knockout phenotypes in E. coli,
though no similar mechanisms have yet been described in
mitochondria. The major decrease in oxygen consumption
capacity produced by Lon downregulation can be explained
by Lon’s dual function as a protease and as a chaperone
[23]. Lon removes damaged enzymes, such as oxidized
aconitase, from the matrix [24]. Lon also assists with the
folding and assembly of the matrix and inner membrane
respiratory chain complexes [23,31] during their processing
inside the mitochondrial matrix, following synthesis (for the
mitochondrially encoded subunits), or after import into
mitochondria (for the nuclear encoded subunits).
Changes in mitochondrial morphology argue for a rather
complex and heterogenous mechanism, probably also
dependent on the levels of Lon required for a specific
function in each distinctive mitochondrial population. The
presence of electron-dense inclusion bodies inside mito-
chondria, which are presumably formed from aggregated
proteins, confirms our previous observations that oxidized
aconitase (and other damaged proteins) accumulate during
Lon proteolytic deficiency [24]. Mitochondria with little or
no cristae (U0-like mitochondria) seen by electron micro-
scopy, and the emergence of a cell subpopulation with
decreased mitochondrial content, are more evidence of
Lon’s function in maintaining mtDNA integrity and
stimulating mitochondrial biogenesis. While no homolog
of the DNA damage-induced SulA, which acts as a cell
division inhibitor after ultraviolet light damage [13], has
been described in mitochondria, the appearance of giant
mitochondrial bodies inside the cytoplasm of Lon-deficient
WI-38 VA-13 fibroblasts suggests that the lack of septation
and filamentous growth [15] which characterize the DLon/
La E. coli strains might be also taking place in these cell’s
mitochondria.
In conclusion, Lon protease emerges as a major
controller of multiple human mitochondrial functions,including the assembly of respiratory chain protein com-
plexes, the degradation of (oxidatively) damaged proteins,
and the maintenance of mitochondrial DNA integrity.
However, although the protease is highly conserved
[17,27,28], some of its functions might not be the same,
or be performed in the same manner, in different
organisms. In E. coli, protease Lon/La is involved in a
number of adaptative processes, either by selective degra-
dation of short-lived regulatory proteins such as UmuD and
UmuC of the SOS response [12] or by generalized
degradation of free ribosomal proteins [16]. Only a few
specific substrates of Lon protease have been identified in
mammalian systems [24], and none of them should be
involved in mitochondrial DNA maintenance. However,
Lon homeostasis is crucial to mammalian cell fate, as lon
upregulation is associated with tumorigenic transformation
[62] and lon downregulation leads to apoptosis. Thus,
further studies in animal systems are needed to explain the
specific pathways controlled by Lon, and to develop an
advanced understanding of Lon involvement in apoptosis
and carcinogenesis.Acknowledgment
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